The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate's activity in cancer cells

Current Cancer Drug Targets

Volumn 9, Issue 1, 2009, Pages 72-80

  Konkimalla, V Badireenath ^a   McCubrey, James A ^b   Efferth, Thomas ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Artesunate; Cancer; Chemotherapy; EGFR; Molecular pharmacology; Natural products

Indexed keywords

ARTESUNATE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; RAS PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA VECTOR; DRUG RESPONSE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

ARTEMISININS; CELL LINE; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 62749166519     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909787314020     Document Type: Article

References (75)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Carpiuc, K. T.; Stephens, J. M.; Botteman, M. F.; Feng, W.; Hay, J. W. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin. Pharmacotherapy 2007, 8, 2775-2787.
3. Eiermann, W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann. Oncol. 2001, 12, S57-S62.
4. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
5. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
6. Sebolt-Leopold, J. S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4, 937-947.
7. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773, 1263-1284.
8. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26, 3291-3310.
9. Steelman, L. S.; Pohnert, S. C.; Shelton, J. G.; Franklin, R. A.; Bertrand, F. E.; McCubrey, J. A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18, 189-218.
10. McCubrey, J. A.; Steelman, L. S.; Franklin, R. A.; Abrams, S. L.; Chappell, W. H.; Wong, E. W.; Lehmann, B. D.; Terrian, D. M.; Basecke, J.; Stivala, F.; Libra, M.; Evangelisti, C.; Martelli, A. M. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv. Enzyme Regul. 2007, 47, 64-103.
11. Cuni, S.; Perez-Aciego, P.; Perez-Chacon, G.; Vargas, J. A.; Sanchez, A.; Martin-Saavedra, F. M.; Ballester, S.; Garcia-Marco, J.; Jorda, J.; Durantez, A. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18, 1391-1400.
12. Kubota, Y.; Ohnishi, H.; Kitanaka, A.; Ishida, T.; Tanaka, T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 2004, 18, 1438-1440.
13. Efferth, T.; Fu, Y. J.; Zu, Y. G.; Schwarz, G.; Konkimalla, V. S.; Wink, M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr. Med. Chem. 2007, 14, 2024-2032.
14. Efferth, T.; Giaisi, M.; Merling, A.; Krammer, P. H.; Li-Weber, M. Artesunate induces ROS-mediated apoptosis in doxorubicinresistant T leukemia cells. PLoS ONE 2007, 2, e693.
15. Efferth, T.; Li, P. C.; Konkimalla, V. S.; Kaina, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13, 353-361.
16. Efferth, T.; Rücker, G.; Falkenberg, M.; Manns, D.; Olbrich, A.; Fabry, U.; Osieka, R. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittel-Forschung 1996, 46, 196-200.
17. Efferth, T.; Dunstan, H.; Sauerbrey, A.; Miyachi, H.; Chitambar, C. R. The anti-malarial artesunate is also active against cancer. Int. J.Oncol. 2001, 18, 767-773.
18. Kelter, G.; Steinbach, D.; Konkimalla, V. B.; Tahara, T.; Taketani, S.; Fiebig, H. H.; Efferth, T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2007, 2, e798.
19. Efferth, T.; Briehl, M. M.; Tome, M. E. Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. 2003, 23, 1231-1235.
20. Efferth, T.; Davey, M.; Olbrich, A.; Rücker, G.; Gebhart, E.; Davey, R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrugresistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 2002, 28, 160-168.
21. Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H. O.; Hengstler, J. G.; Halatsch, M. E.; Volm, M.; Tew, K. D.; Ross, D. D.; Funk, J. O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64, 382-394.
22. Efferth, T.; Oesch, F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 2004, 68, 3-10.
23. Dell'Eva, R.; Pfeffer, U.; Vene, R.; Anfosso, L.; Forlani, A.; Albini, A.; Efferth, T. Inhibition of angiogenesis in vivo and growth of Ka posi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 2004, 68, 2359-2366.
24. Berger, T. G.; Dieckmann, D.; Efferth, T.; Schultz, E. S.; Funk, J.O.; Baur, A.; Schuler, G. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 2005, 14, 1599-1603.
25. Efferth, T.; Ramirez, T.; Gebhart, E.; Halatsch, M. E. Combination treatment of glioblastoma multiforme cell lines with the antimalarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. 2004, 67, 1689-1700.
26. McCubrey, J.; Holland, G.; McKearn, J.; Risser, R. Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms. Oncogene Res. 1989, 4, 97-109.
27. McCubrey, J. A.; Smith, S. R.; Algate, P. A.; DeVente, J. E.; White, M. K.; Steelman, L. S. Retroviral infection can abrogate the factor-dependency of hematopoietic cells by autocrine and nonautocrine mechanisms depending on the presence of a functional viral oncogene. Oncogene 1993, 8, 2905-2915.
28. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
29. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.
30. Scherf, U.; Ross, D. T.; Waltham, M.; Smith, L. H.; Lee, J. K.; Tanabe, L.; Kohn, K. W.; Reinhold, W. C.; Myers, T. G.; Andrews, D. T.; Scudiero, D. A.; Eisen, M. B.; Sausville, E. A.; Pommier, Y.; Botstein, D.; Brown, P. O.; Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244.
31. Staunton, J. E.; Slonim, D. K.; Coller, H. A.; Tamayo, P.; Angelo, M. J.; Park, J.; Scherf, U.; Lee, J. K.; Reinhold, W. O.; Weinstein, J. N.; Mesirov, J. P.; Lander, E. S.; Golub, T. R. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 2001, 98, 10787-10792.
32. Grant, S.; Qiao, L.; Dent, P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 2002, 7, d376-389.
33. Shaul, Y. D.; Seger, R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 2007, 1773, 1213-1226.
34. Navolanic, P. M.; Steelman, L. S.; McCubrey, J. A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 2003, 22, 237-252.
35. Martelli, A. M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Cappellini, A.; Billi, A. M.; Cocco, L. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol. Histopathol. 2005, 20, 239-252.
36. Poeta, D. G.; Bruno, A.; Principe, M. I.; Venditti, A.; Maurillo, L.; Buccisano, F.; Stasi, R.; Neri, B.; Luciano, F.; Siniscalchi, A.; de Fabritiis, P.; Amadori, S. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr. Cancer Drug Targets 2008, 8, 207-222.
37. Frackelton, A. R.; Lu, L.; Davol, P. A.; Bagdasaryan, R.; Hafer, L. J.; Sgroi, D. C. p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy. Breast Cancer Res. 2006, 8, R73.
38. Swanton, C.; Downward, J. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell 2008, 13, 83-85.
39. Woessmann, W.; Chen, X.; Borkhardt, A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 2002, 50, 397-404.
40. Deng, X.; Kornblau, S. M.; Ruvolo, P. P.; May, W. S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J. Natl. Cancer Inst. Monogr. 2001, 28, 30-37.
41. Butt, A. J.; Caldon, C. E.; McNeil, C. M.; Swarbrick, A.; Musgrove E. A.; Sutherland R. L. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv. Exp. Med. Biol. 2008, 630, 189-205.
42. Biliran, H.; Banerjee, S.; Thakur, A.; Sarkar, F. H.; Bollig, A.; Ahmed, F.; Wu, J.; Sun, Y.; Liao, J. D. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin. Cancer Res. 2007, 13, 2811-2821.
43. Stam, J. C.; Geerts, W. J.; Versteeg, H. H.; Verkleij, A. J.; Henegouwen, P. M. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. J. Biol. Chem. 2001, 276, 25176-25183.
44. Huan-huan, C.; Li-Li, Y.; Shang-Bin, L. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett. 2004, 211, 163-173.
45. Wu, G. D.; Zhou, H. J.; Wu, X. H. Apoptosis of human umbilical vein endothelial cells induced by artesunte. Vasc. Pharmacol. 2004, 41, 205-212.
46. McCubrey, J. A.; Shelton, J. G.; Steelman, L. S.; Franklin, R. A.; Sreevalsan, T.; McMahon, M. Conditionally active v-ErbB:ER transforms NIH-3T3 cells and converts human and mouse cells to cytokine-independence. Oncogene 2004, 23, 7810-7820.
47. Shelton, J. G.; Steelman, L. S.; Abrams, S. L.; White, E. R.; Akula, S. M.; Bertrand, F. E.; Franklin, R. A.; McCubrey, J. A. Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine -dependent hematopoietic cell line. Cell Cycle 2005, 4, 818-821.
48. Shelton, J. G.; Steelman, L. S.; Abrams, S. L.; White, E. R.; Akula, S. M.; Bertrand, F. E.; Franklin, R. A.; McCubrey, J. A. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005, 4, 822-830.
49. McCubrey, J. A.; Steelman, L. S.; Hoyle, P. E.; Blalock, W. L.; Weinstein-Oppenheimer, C.; Franklin, R. A.; Cherwinski, H.; Bosch, E.; McMahon, M. Differential Abilities of Activated Raf Oncoproteins to Abrogate Cytokine-Dependency, Prevent Apoptosis and Induce Autocrine Growth Factor Synthesis in Human Hematopoietic Cells. Leukemia 1998, 12, 1903-1929.
50. Hoyle, P. E.; Moye, P. W.; Steelman, L. S.; Blalock, W. L.; Franklin, R. A.; Pearce, M.; Cherwinski, H.; Bosch, E.; McMahon, M.; McCubrey, J. A. Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000, 14, 642-656.
51. McCubrey, J. A.; Steelman, L. S.; Moye, P. W.; Hoyle, P. E.; Weinstein-Oppenheimer, C. L.; Chang, F.; Pierce, M.; White, M. K.; Franklin, R.; Blalock, W. L. Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells. Adv. Enzyme Regul. 2000, 40, 305-337.
52. Moye, P. W.; Blalock, W. L.; Hoyle, P. E.; Chang, F.; Franklin, R. A.; Weinstein-Oppenheimer, C.; Pearce, M.; Steelman, L.; McMahon, M.; McCubrey, J. A. Synergy Between Raf and BCL2 in Abrogating the Cytokine-Dependency of Hematopoietic Cells. Leukemia 2000, 14, 1060-1079.
53. Weinstein-Oppenheimer, C.; Steelman, L. S.; Algate, P. A.; Blalock, W. L.; Burrows, C.; Hoyle, P. E.; Lee, J. T.; Moye, P. W.; Shelton, J. G.; Franklin, R. A.; McCubrey, J. A. Effects of Deregulated Raf Activation on Integrin, Cytokine-Receptor Expression and the Induction of Apoptosis in Hematopoietic Cells. Leukemia 2000, 14, 1921-1938.
54. McCubrey, J. A.; Steelman, L. S.; Blalock, W. L.; Lee, J. T.; Moye, P. W.; Chang, F.; Pearce, M.; Shelton, J. G.; White, M. K.; Franklin, R. A.; Pohnert, S. C. Synergistic Effects of PI3K/Akt on Abrogation of Cytokine-Dependency Induced by Oncogenic Raf. Adv. Enzyme Regul. 2001, 289-323.
55. Chang, F.; McCubrey, J. A. p21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001, 20, 4353-4364.
56. McCubrey, J. A.; Lee, J. T.; Steelman, L. S.; Blalock, W. L.; Moye, P. W.; Chang, F.; Pearce, M.; Shelton, J. G.; White, M. K.; Frank lin, R. A.; Pohnert, S. C. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect. Prevent. 2001, 25, 375-393.
57. Chang, F.; Steelman, L. S.; McCubrey, J. A. Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells. Cell Cycle 2002, 1, 220-227.
58. Shelton, J. G.; Steelman, L. S.; Lee, J. T.; Knapp, S. L.; Blalock, W. L.; Moye, P. M.; Franklin, R. A.; Pohnert, S. C.; Mizra, A. M.; McMahon, M.; McCubrey, J. A. Effects of the Raf/MEK/ERK and PI3K signal transduction pathways on the abrogation of cytokine dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003, 24, 2478-2492.
59. Shelton, J. G.; Chang, F.; Lee, J. T.; Franklin, R. A.; Steelman, L. S.; McCubrey, J. A. B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle 2004, 3, 189-196.
60. Shelton, J. G.; Steelman, L. S.; White, E. R.; McCubrey, J. A. Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells. Cell Cycle 2004, 3, 372-379.
61. Demidenko, Z. N.; Halicka, D.; Kunicki, J.; McCubrey, J. A.; Darzynkiewicz, Z.; Blagosklonny, M. V. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1- expressing) cancer cells by docetaxel. Cancer Res. 2005, 65, 4401-4407.
62. Demidenko, Z. N.; An, W. G.; Lee, J. T.; Romanova, L. Y.; McCubrey, J. A.; Blagosklonny, M. V. Kinase-Addiction and Bi-Phasic Sensitivity-Resistance of Bcr-Abl- and Raf-1-Expressing Cells to Imatinib and Geldanamycin. Cancer Biol. Ther. 2005, 4, 484-490.
63. Konopleva, M.; Shi, Y.; Steelman, L. S.; Shelton, J. G.; Munsell, M.; Marini, F.; McQueen, T.; Contractor, R.; McCubrey, J. A.; Andreeff, M. Development of a conditional in vivo model to evaluate the efficacy of Small Molecule Inhibitors for the Treatment of Raf Transformed Hematopoietic Cells. Cancer Res. 2005, 65, 9962-9970.
64. Hamden, K. E.; Ford, P. W.; Whitman, A. G.; McCubrey, J. A.; Akula, S. M. Raf induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8) Infection. J. Virol. 2004, 78, 13381-13390.
65. Akula, S. M.; Ford, P. W.; Whitman, A. G.; Hamden, K. H.; Shelton, J. G.; McCubrey J. A. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene 2004, 23, 5227-5241.
66. Akula, S. M.; Ford, P. W.; Whitman, A. G.; Hamden, K. E.; Bryan, B. A.; Cook, P. P.; McCubrey, J. A. B-Raf dependent expression of vascular endothelial growth factor-A in Kaposi's sarcomaassociated herpesvirus infected human B cells. Blood 2005, 105, 4516-4522.
67. Lee, J. T.; Steelman, L. S.; McCubrey, J. A. Modulation of Raf/MEK/ERK pathway in prostate cancer drug resistance. Int. J. Oncol. 2005, 26, 1637-1645.
68. Weinstein-Oppenheimer, C. R.; Henríquez-Roldán, C. F.; Davis, J.; Navolanic, P. M.; Saleh, O. A.; Steelman, L. S.; Franklin, R. A.; Robinson, P. J.; McMahon, M.; McCubrey, J. A. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin. Cancer Res. 2001, 7, 2892-2907.
69. Davis, J. M.; Weinstein-Oppenheimer, C. R.; Steelman, L. S.; Navolanic, P. N.; Hu, W.; Konopleva, M.; Blagosklonny, M. V.; McCubrey, J. A. Raf-1 and Bcl-2 Induce Distinct and Common Pathways Which Contribute to Breast Cancer Drug Resistance. Clin. Cancer Res. 2003, 9, 1161-1170.
70. Blalock, W. L.; Pearce, M.; Steelman, L. S.; Franklin, R. A.; McCarthy, S. A.; Cherwinski, H.; McMahon, M.; McCubrey, J. A. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoeitic cells. Oncogene 2000, 19, 526-536.
71. Blalock, W. L.; Moye, P. W.; Chang, F.; Pearce, M.; Steelman, L. S.; McMahon, M.; McCubrey, J. A. Combined Effects of Aberrant MEK1 Activity and BCL2 Overexpression on Relieving the Cytokine-Dependency of Human and Murine Hematopoietic Cells. Leukemia 2000, 14, 1080-1096.
72. Blalock, W. L.; Pearce, M.; Chang, F.; Lee, J.; Pohnert, S.; Burrows, C.; Steelman, L. S.; Franklin, R. A.; McMahon, M.; McCubrey, J. A. Effects of Inducible MEK1 Activation on the Cytokine-Dependency of Lymphoid Cells. Leukemia 2001, 15, 794-807.
73. Blalock, W. L.; Steelman, L. S.; Shelton, J. G.; Moye, P. W.; Lee, J. T.; Franklin, R. A.; Mirza, A.; McMahon, M.; White, M. K.; McCubrey, J. A. Requirement for the PI3K/Akt Pathway in MEK1-Mediated Growth and Prevention of Apoptosis: Identification of an Achilles Heel in Leukemia. Leukemia 2003, 17, 1058-1067.
74. Shelton, J. G.; Moye, P. W.; Steelman, L. S.; Blalock, W. L.; Lee, J. T.; Franklin, R. A.; McMahon, M.; McCubrey, J. A. Differential effects of kinase cascade inhibitors on neoplastic and cytokinemediated cell proliferation. Leukemia 2003, 17, 1765-1782.
75. Shelton, J. G.; Blalock, W. L.; White, E. R.; Steelman, L. S.; McCubrey, J. A. Ability of the Activated PI3K/Akt Oncoproteins to Synergize with MEK1 and Induce Cell Cycle Progression and Abrogate the Cytokine-Dependence of Hematopoietic Cells. Cell Cycle 2004, 3, 503-512.